ESC Clinical Practice Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes:

have I got heart atherosclerotic CVD? failure? I have diabetes, I have diabetes, I have atherosclerotic I have heart failure, have I got chronic what is my 10-year CVD, have I got have I got diabetes? kidney disease? cardiovascular risk? diabetes? Medications To Lower Cardiovascular Risk The ESC Guidelines recommend certain heart-protective medications based on whether you have diabetes, atherosclerotic cardiovascular disease, heart failure and/or chronic kidney disease. These medications are added to your existing treatments, regardless of your glucose control or glucose- lowering therapies given for diabetes. If you have type 2 diabetes and atherosclerotic cardiovascular disease, it is recommended that you receive both a GLP-1 RA and an SGLT2 inhibitor with proven cardiovascular benefit to reduce cardiovascular risk If you have type 2 diabetes and heart failure, it is recommended that you receive an SGLT2 inhibitor with proven cardiovascular benefit to reduce hospital stays due to worsening heart failure • You should receive an SGLT2 inhibitor regardless of the type of heart failure that you have If you have type 2 diabetes and chronic kidney disease, it is recommended that you receive an SGLT2 inhibitor to reduce the cardiovascular and kidney failure risk • To further reduce the
